0JQ2.L

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$25M	-39.5%	$-26.50	$-26.50–$-26.50	—	1
2027	$26M	+4.5%	$-20.00	$-20.00–$-20.00	—	1
2028	$134M	+413.9%	$-9.00	$-9.00–$-9.00	—	1
2029	$229M	+70.9%	$-8.50	$-8.50–$-8.50	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-19	$-6.00	$-21.32	-255.3%
2026-05-15	$-8.50	$-0.14	+98.4%
2026-04-15	$-16.00	$1.23	+107.7%
2025-11-19	$-50.50	$-53.50	-5.9%
2025-08-08	$-1.70	$-1.71	-0.4%
2025-05-14	$-101.50	$-70.50	+30.5%
2025-03-28	$-114.00	$-87.00	+23.7%
2024-11-12	$-121.50

DCF fair valuemodel estimate

Intrinsic value

$40.65

Price

$0.52

Implied upside

+7709%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
0JQ2.LKALA BIO, Inc.	$0.54	+3.32%	$75532	—
0HL9.LAffimed N.V.	$0.00	+0.00%	$1540	—
0JW9.LLite Strategy, Inc.	$1.05	+1.94%	$7M	—
0KF3.LPalatin Technologies, Inc.	$10.17	-14.10%	$10M	—
0L85.LSorrento Therapeutics, Inc.	$0.00	+420.00%

KALA BIO, Inc.

Kala Bio, Inc. operates as a biopharmaceutical enterprise focused on developing and bringing to market innovative treatments. The company employs its unique, proprietary nanoparticle technology, designed to effectively penetrate mucus barriers. Initially, its efforts are concentrated on addressing various ocular conditions. Established in 2009 by founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, the firm maintains its headquarters in Arlington, Massachusetts.

www.kalarx.com

Employees: 6
IPO / List date: Jan 29, 2018
HQ: US

Held by traders on TradeandTell

No one on the platform currently holds 0JQ2.L.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 0JQ2.L as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 0JQ2.L yet.